Medscape6d
Dipeptidyl Peptidase-4 Inhibitors: Clinical Data and Clinical Implications
The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1 ... in studies up to 52 weeks. Also in combination with metformin ...
Medpage Today on MSN4d
GLP-1 Drugs Tied to Reduced Risk of Dangerous Blood Clots
Type 2 diabetes patients may have a lower risk of venous thromboembolism (VTE) when treated with a GLP-1 receptor agonist, ...
Hosted on MSN28d
ASH: GLP-1 RA Use Tied to Lower Rate of Venous Thromboembolism in Diabetes
Patients who received GLP-1 RAs were compared to those who received dipeptidyl peptidase-4 (DPP-4) inhibitors; after propensity score matching, the final analysis included two cohorts of 168 ...
clinicaladvisor.com1mon
SGLT-2 Inhibitors Beneficial for Patients With Nephrolithiasis
Reduction seen in recurrent nephrolithiasis events for those receiving SGLT-2 inhibitors vs GLP-1 RAs, DPP-4 inhibitors. HealthDay News — For patients with nephrolithiasis, sodium-glucose ...
Monthly Prescribing Reference6y
Jentadueto Xr
Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose ... to linagliptin if used in combination. Diuretics, ...
Medical Xpress29d
GLP-1 RA use tied to lower rate of venous thromboembolism in diabetes
Patients who received GLP-1 RAs were compared to those who received dipeptidyl peptidase-4 (DPP-4) inhibitors; after propensity score matching, the final analysis included two cohorts of 168 ...